Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action; Journal of Personalized Medicine; Vol. 11, iss. 8

Bibliografiska uppgifter
Parent link:Journal of Personalized Medicine
Vol. 11, iss. 8.— 2021.— [731, 8 p.]
Institutionell upphovsman: Национальный исследовательский Томский политехнический университет Инженерная школа неразрушающего контроля и безопасности Отделение контроля и диагностики
Övriga upphovsmän: Ochi T. Taichi, Vyalova N. M. Nataljya Mikhaylovna, Losenkov I. S. Innokenty Sergeevich, Paderina D. Z. Diana, Pozhidaev I. V. Ivan Vyacheslavovich, Loonen A. J. M. Anton, Simutkin G. G. German Gennadjevich, Bokhan N. A. Nikolay Aleksandrovich, Wilffert B. Bob, Ivanova S. A. Svetlana Aleksandrovna
Sammanfattning:Title screen
Background: There is sufficient evidence that interference of dopaminergic neurotransmission contributes to the therapeutic effects of antidepressants in unipolar and bipolar depression. Methods: Hamilton depression rating scale (HAMD 17) scores of 163 at least moderately ill patients with major depressive disorders were used to establish treatment response. HAMD 17 score status was measured before initiation, after two weeks, and after four weeks of treatment with various antidepressants. The possible association between response and genotype in a total of 14 variants of dopamine neurotransmission-related proteins was investigated. Results: DRD4 rs11246226 CA heterozygous patients were found with a greater improvement of HAMD 17 score when compared to homozygous C patients during 0-2 weeks and 0-4 weeks. Patients with MAOB rs1799836 heterozygous GA and homozygous A also demonstrated improved scores during 2-4 weeks and 0-4 weeks. Conclusions: The results are preliminary due to the limited population size and the small number of variants. Further research into the involvement of habenular dopamine D4 receptors in the antidepressant response is desirable.
Språk:engelska
Publicerad: 2021
Ämnen:
Länkar:https://doi.org/10.3390/jpm11080731
Materialtyp: Elektronisk Bokavsnitt
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=666406

MARC

LEADER 00000naa0a2200000 4500
001 666406
005 20250215163256.0
035 |a (RuTPU)RU\TPU\network\37610 
035 |a RU\TPU\network\37603 
090 |a 666406 
100 |a 20211223d2021 k||y0rusy50 ba 
101 0 |a eng 
135 |a drgn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action  |f T. Ochi, N. M. Vyalova, I. S. Losenkov [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 37 tit.] 
330 |a Background: There is sufficient evidence that interference of dopaminergic neurotransmission contributes to the therapeutic effects of antidepressants in unipolar and bipolar depression. Methods: Hamilton depression rating scale (HAMD 17) scores of 163 at least moderately ill patients with major depressive disorders were used to establish treatment response. HAMD 17 score status was measured before initiation, after two weeks, and after four weeks of treatment with various antidepressants. The possible association between response and genotype in a total of 14 variants of dopamine neurotransmission-related proteins was investigated. Results: DRD4 rs11246226 CA heterozygous patients were found with a greater improvement of HAMD 17 score when compared to homozygous C patients during 0-2 weeks and 0-4 weeks. Patients with MAOB rs1799836 heterozygous GA and homozygous A also demonstrated improved scores during 2-4 weeks and 0-4 weeks. Conclusions: The results are preliminary due to the limited population size and the small number of variants. Further research into the involvement of habenular dopamine D4 receptors in the antidepressant response is desirable. 
461 |t Journal of Personalized Medicine 
463 |t Vol. 11, iss. 8  |v [731, 8 p.]  |d 2021 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a dopaminergic pathway 
610 1 |a depression 
610 1 |a antidepressants 
610 1 |a mood disorders 
610 1 |a dopamine 
610 1 |a pharmacogenetics 
610 1 |a депрессия 
610 1 |a антидепрессанты 
610 1 |a расстройства 
701 1 |a Ochi  |b T.  |g Taichi 
701 1 |a Vyalova  |b N. M.  |g Nataljya Mikhaylovna 
701 1 |a Losenkov  |b I. S.  |g Innokenty Sergeevich 
701 1 |a Paderina  |b D. Z.  |g Diana 
701 1 |a Pozhidaev  |b I. V.  |g Ivan Vyacheslavovich 
701 1 |a Loonen  |b A. J. M.  |g Anton 
701 1 |a Simutkin  |b G. G.  |g German Gennadjevich 
701 1 |a Bokhan  |b N. A.  |g Nikolay Aleksandrovich 
701 1 |a Wilffert  |b B.  |g Bob 
701 1 |a Ivanova  |b S. A.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1964-  |g Svetlana Aleksandrovna  |3 (RuTPU)RU\TPU\pers\33859 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Инженерная школа неразрушающего контроля и безопасности  |b Отделение контроля и диагностики  |3 (RuTPU)RU\TPU\col\23584 
801 2 |a RU  |b 63413507  |c 20211223  |g RCR 
856 4 |u https://doi.org/10.3390/jpm11080731 
942 |c CF